Pull to refresh
Logo
Insilico Medicine releases AI models that beat dedicated drug-discovery software

Insilico Medicine releases AI models that beat dedicated drug-discovery software

New Capabilities

Language-model specialists trained through MMAI Gym match or surpass established computational methods across 50+ benchmarks

2 days ago: Frontier specialist AI models released

Overview

Updated 47 minutes ago

Insilico Medicine released AI models Sept. 2 that it says outperform the dedicated software drug companies have used for years. The language-model specialists cover chemical synthesis, drug-safety prediction, and target-binding strength.

The Hong Kong-listed company reports state-of-the-art or better scores on more than 50 benchmark tasks, including 28 drug-safety endpoints covering absorption, distribution, metabolism, excretion, and toxicity. Insilico licenses its platform to 13 of the world's top 20 pharmaceutical firms, so the models face real-world testing quickly.

The open question is whether benchmark wins survive real drug programs. Insilico's lead drug, the AI-discovered rentosertib, is in Phase III trials for a lung disease. The company nominated nine development candidates in the first nine months of 2026.

Why it matters

If language-model AI reliably predicts drug safety and potency before lab work, early discovery gets faster and cheaper — and more candidates reach human trials sooner.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

50+
Benchmark tasks with state-of-the-art or better scores
Across chemistry and biology, verified on the company's DDD Bench framework.
13 of 20
Top pharmaceutical firms licensing Insilico's platform
Licensing gives the new models a fast path to commercial use.
9
Development candidates nominated in nine months of 2026
A company record for annual pipeline productivity, driven by the Pharma.AI platform.
$600M
Potential total value of Takeda collaboration
Includes initiation fees, near-term payments, milestones, and tiered royalties.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

June 2014 September 2026

3 events Latest: 2 days ago
  1. Frontier specialist AI models released

    Latest Product Release

    Insilico releases chemistry and biology specialists trained via MMAI Gym, claiming state-of-the-art performance on more than 50 benchmark tasks.

  2. Insilico and Liquid AI announce partnership

    Partnership

    The companies unveil LFM2-2.6B-MMAI, a lightweight scientific foundation model for pharmaceutical research.

  3. Insilico Medicine founded

    Founding

    Alex Zhavoronkov founds the company in Baltimore to apply AI to aging research and drug discovery.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1980-2000

Computer-aided drug design, 1980s-1990s

Molecular-modeling and docking software met deep skepticism from bench chemists who trusted wet-lab instincts, and early failures slowed acceptance.

Then

One tool at a time, computational methods earned niches in lead optimization and scoring.

Now

CADD became a standard part of discovery, not a replacement for experiments, shaping what the industry expects from new methods.

Why this matters now

The adoption curve for today's AI mirrors this: breakthrough claims get tested against real programs, and survivors become standard tools rather than wholesale replacements for lab work.

November 2020

AlphaFold (2020)

DeepMind's AlphaFold burst onto protein-structure prediction with results that stunned structural biologists, matching or beating experimental methods after decades of slow progress.

Then

AlphaFold triggered a wave of adoption, with millions of structures predicted and later folded into biology toolkits.

Now

It proved a general AI method could outperform purpose-built scientific software and reset expectations for the field.

Why this matters now

Like AlphaFold, Insilico's models claim to beat tools built specifically for a scientific task. The parallel is also a caution: AlphaFold took years of independent validation before its real limits and uses were understood.

Sources

(7)